Genetic Testing The institute recently launched a genetic test for glaucoma risk (SightScore by Seonix Bio), indicating openness to expanding into genomics-driven diagnostics which can be leveraged for cross-sell of personalized treatment plans and monitoring services.

Advanced Surgical Tech Adoption of cutting-edge equipment such as LENSAR laser technology for complex cataract surgeries suggests the practice values high-performance devices and may be receptive to upgrades, maintenance plans, or new optimization tools.

BlephEx Launch Introduction of BlephEx for blepharitis demonstrates a willingness to adopt new therapeutic modalities; explore partnerships for device sales, consumables, training programs, and clinic-wide patient education packages.

Growth Momentum Revenue range indicates mid-market status with ongoing expansion potential; position complementary services, digital marketing solutions, and patient engagement platforms to support scale and new patient acquisition.

Strategic Focus History of clinical trials involvement and leadership in ophthalmology suggests potential for research collaborations, sponsor opportunities, and enterprise-level service agreements around data analytics, outcomes tracking, and trial partnerships.